Scarica l'app Stockscreener
42.49
1.21%
0.51
Dopo l'orario di chiusura:
41.86
-0.63
-1.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$41.98
Aprire:
$40.95
Volume 24 ore:
1.50M
Relative Volume:
0.62
Capitalizzazione di mercato:
$4.52B
Reddito:
$761.41M
Utile/perdita netta:
$98.16M
Rapporto P/E:
51.94
EPS:
0.8181
Flusso di cassa netto:
$141.79M
1 W Prestazione:
+10.28%
1M Prestazione:
+18.13%
6M Prestazione:
-50.29%
1 anno Prestazione:
-49.30%
Intervallo 1D:
$40.48
$43.37
Intervallo di 1 settimana:
$37.15
$43.37
Portata 52W:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
42.49 | 4.52B | 761.41M | 98.16M | 141.79M | 0.8181 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Iniziato | UBS | Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Corcept Therapeutics Incorporated $CORT Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud LawsuitInvestors Encouraged to Contact Kaplan Fox - NewMediaWire
Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK - MSN
Corcept Therapeutics Faces Class Action Lawsuit - National Today
Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights - aijourn.com
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics IncorporatedCORT - PR Newswire
Corcept (CORT) Class Action Alleges Misstatements on FDA Data ConcernsHagens Berman - ChartMill
Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Share Price Volatility? - finance.yahoo.com
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
CORCEPT THERAPEUTICS DEADLINE: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
CORT Investors Have Opportunity to Lead Corcept - GlobeNewswire
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
Corcept Presents Latest Data from MOMENTUM Trial at ACC.26 - dicardiology.com
ROSEN Law Firm Encourages Corcept Therapeutics Investors - National Today
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to ... - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept - GlobeNewswire
Deadline Alert: Corcept Therapeutics Incorporated (CORT) - GlobeNewswire
User - The Chronicle-Journal
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ - natlawreview.com
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026 - The Globe and Mail
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire
Corcept Therapeutics Incorporated (CORT) Gains on FDA Approval, But Questions Remain - finance.yahoo.com
Corcept Therapeutics Class Action Reminder for Investors - Intellectia AI
Corcept Therapeutics Incorporated Securities Fraud Class - GlobeNewswire
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026 - ACCESS Newswire
CORT INVESTOR UPDATE: Hagens Berman Alerts Corcept - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Bragar Eagel & Squire, P.C. Urges Navan and Corcept - GlobeNewswire
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally - FinancialContent
Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT) - The Globe and Mail
CORT Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Corcept Therapeutics Incorporated Securities Lawsuit -- The Gross Law Firm - PR Newswire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated ... - Caledonian Record
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages - GlobeNewswire
April 21, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CORT - GlobeNewswire
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - ChartMill
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud ... - Caledonian Record
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session - MarketScreener
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $73 - Moomoo
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN Counsel Encourages Corcept Therapeutics - National Today
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated ... - Caledonian Record
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - AOL.com
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):